News
GLUE
--
0.00%
--
Piper Sandler Adjusts Price Target on Monte Rosa Therapeutics to $21 From $40, Reiterates Overweight Rating
MT Newswires · 05/12 05:54
Monte Rosa Therapeutics GAAP EPS of -$0.51 beats by $0.03
Monte Rosa Therapeutics press release (NASDAQ:GLUE): GAAP EPS of -$0.51 beats by $0.03. Cash, cash equivalents, restricted cash and marketable securities as of March 31, 2022, were $322.5 million, compared to cash, cash
Seekingalpha · 05/11 12:00
BRIEF-Monte Rosa Therapeutics Reports First Quarter 2022 Financial Results And Business Updates
reuters.com · 05/11 11:34
Monte Rosa Therapeutics Q1 Net Loss Narrows
MT Newswires · 05/11 08:03
Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2022
 
Benzinga · 04/28 14:09
--Credit Suisse Initiates Monte Rosa Therapeutics at Neutral, $19 Price Target
MT Newswires · 04/28 11:14
Monte Rosa Therapeutics Presents Preclinical Data Highlighting Potential of GSPT1-directed Molecular Glue Degrader MRT-2359 to Target Myc-driven Cancers at AACR Annual Meeting 2022
– Data Highlight Essential Role of GSPT1 in Sustaining Myc-induced Translational Addiction in Solid Tumors – BOSTON, April 08, 2022 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue de...
GlobeNewswire · 04/08 17:00
Berenberg Bank Adjusts Monte Rosa Therapeutics' Price Target to $28 From $32, Maintains Buy Rating
MT Newswires · 03/30 07:25
Monte Rosa Therapeutics GAAP EPS of -$2.96 misses by $0.43
Monte Rosa Therapeutics press release (NASDAQ:GLUE): FY GAAP EPS of -$2.96 misses by $0.43. Cash, cash equivalents and restricted cash as of December 31, 2021, were $351.4 million, compared to $42.9 million as
Seekingalpha · 03/29 12:09
BRIEF-Monte Rosa Says Year-End Cash, Cash Equivalents To Provide Runway Into Late 2024
reuters.com · 03/29 11:35
Monte Rosa Therapeutics Full-Year 2021 Net Loss Narrows
MT Newswires · 03/29 07:58
Clover Health, Monte Rosa top healthcare gainers; Atreca, Biophytis lead losers' pack
Gainers: Clover Health Investments (NASDAQ:CLOV) +18%. Monte Rosa Therapeutics (NASDAQ:GLUE) +12%. Sharecare (NASDAQ:SHCR) +10%. InflaRx (NASDAQ:IFRX) +9%. Sigilon Therapeutics (NASDAQ:SGTX) +9%. Losers: Atreca (NASDAQ:BCEL) -30%. Biophytis (NASDAQ:BPTS) -...
Seekingalpha · 03/07 15:01
--Wells Fargo Starts Monte Rosa Therapeutics at Equalweight With $19 Price Target
MT Newswires · 02/09 19:12
Monte Rosa Therapeutics Announces Participation in Upcoming Investor Conferences
BOSTON, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader medicines, today announced that the company is scheduled to present at the following upcoming investor ...
GlobeNewswire · 02/03 21:30
ETRN, PIXY and UONE among mid-day movers
Gainers: Sierra Oncology (NASDAQ:SRRA) +46%. Aptorum Group (NASDAQ:APM) +38%. Bally's (NYSE:BALY) +24%. SmileDirectClub (NASDAQ:SDC) +20%. Virgin Orbit (NASDAQ:VORB) +16%. Allscripts Healthcare Solutions (NASDAQ:MDRX) +15%. Turquoise Hill Resources (NYSE:T...
Seekingalpha · 01/25 17:48
Monte Rosa falls 11% amid research collaboration for molecular glue degraders
Monte Rosa Therapeutics (NASDAQ:GLUE) signed a license and research collaboration agreement with Nir London and the Yeda Research and Development Company to accelerate the discovery and development of novel covalent molecular
Seekingalpha · 01/25 16:42
Monte Rosa Therapeutics Teams Up with Yeda Research for Molecular Glue Degraders
MT Newswires · 01/25 12:43
Monte Rosa Therapeutics And Yeda Announce License And Research Collaboration To Accelerate Discovery Of Novel Covalent Molecular Glue Degraders
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a biotechnology company developing novel molecular glue degrader medicines, announced a license and research collaboration agreement with Dr. Nir London and the Yeda Research
Benzinga · 01/25 12:35
Monte Rosa Therapeutics and Yeda, the commercial arm of the Weizmann Institute of Science, Announce License and Research Collaboration to Accelerate Discovery of Novel Covalent Molecular Glue Degraders
BOSTON and REHOVOT, Israel, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader medicines, announced a license and research collaboration agreement with Dr. Nir Lo...
GlobeNewswire · 01/25 12:30
Monte Rosa Therapeutics EPS beats by $0.03
Monte Rosa Therapeutics (NASDAQ:GLUE): Q3 GAAP EPS of -$0.43 beats by $0.03. Cash and cash equivalents as of Sept. 30, 2021, were $367.0 million. Press Release
Seekingalpha · 11/10/2021 14:12
Webull provides a variety of real-time GLUE stock news. You can receive the latest news about Monte Rosa Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About GLUE
Monte Rosa Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in developing a portfolio of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically relevant proteins. It develops a protein degradation platform, called QuEEN, that enables it to identify protein targets and molecular glue degrader (MGD), product candidates that are designed to eliminate therapeutically relevant proteins. It focuses on therapeutic targets backed by biological and genetic rationale discovering and developing novel precision medicines. It utilizes its Quantitative and Engineered Elimination of Neosubstrates (QuEEN), platform to design novel MGDs focused on delivering therapies to targets that have been considered undruggable or inadequately drugged in biological pathways across clinical indications in oncology and non-oncology, including immunology, inflammation, neurological and genetic diseases.